度洛西汀和阿米替林对抑郁症患者生命质量的影响

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (1): 67-71.

度洛西汀和阿米替林对抑郁症患者生命质量的影响

王继辉, 吴小立, 魏钦令, 韩自力

中山大学附属第三医院心理科,广州 510630,广东

收稿日期:2010-12-13 修回日期:2011-01-11 发布日期:2020-09-16
通讯作者: 韩自力,男,硕士,副教授,研究方向:司法精神医学。Tel: 13312883609 E-mail: 13312883609@189.cn
作者简介:王继辉,男,硕士,主治医师,研究方向:焦虑障碍。Tel: 13560102194 E-mail: jonny928@126.com
基金资助:
2009广东省自然科学基金(9151008901000065)

A comparative study of efficacy on the quality of life between duloxetine and amitriptyline in treating patients with depression

WANG Ji-hui, WU Xiao-li, WEI Qin-ling, HAN Zi-li

Department of Psychology,3rd Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630,Guangdong, China

Received:2010-12-13 Revised:2011-01-11 Published:2020-09-16

摘要/Abstract

摘要： 目的: 研究度洛西汀和阿米替林对抑郁症患者生命质量的影响,以及生命质量和疗效及药物副作用的相关性。方法: 将57例抑郁症患者随机分为度洛西汀组(研究组,30例)和阿米替林组(对照组,27例),疗程6周。在基线和1、2、4、6周后,给予评定健康状况问卷(SF-36)、汉密尔顿抑郁量表(HAMD) (24项版)、汉密尔顿焦虑量表(HAMA)、治疗过程出现症状量表(TESS)。结果: 治疗6周后,研究组和对照组有效率相近,分别为 86.67%(26/30)、85.19%(23/27),P＞0.05;痊愈率相近,分别为 46.67%(14/30)、44.44%(12/27),P＞0.05;对照组不良反应发生率高于研究组(77.78％ vs 36.67％, P<0.05);治疗6周后,研究组SF-36各因子分均高于对照组(P<0.05)。SF-36多项因子分的提高和HAMD减分率、HAMA减分率成正相关,和TESS总分成负相关(P<0.05)。结论: 度洛西汀对抑郁症患者生命质量的改善优于阿米替林;抑郁症患者生命质量和焦虑、抑郁情绪的改善及药物治疗的副作用密切相关。

关键词: 抑郁症, 生命质量, 度洛西汀, 阿米替林

Abstract: AIM: To study the efficacy on the quality of life between duloxetine and amitriptyline in treating patients with depression.METHODS: 57 patients were randomized to either duloxetine group( research group, n=30) or amitriptyline group (control group, n=27) for a 6-week period treatment. All patients were assessed with Short-Form-36 Health Survey (SF-36), Hamilton Depression Scale (HAMD, 24-items), Hamilton Anxiety Scale (HAMA) and the Treatment Emergent Symptom Scale (TESS) before treatment and at the ends of the 1st, 2nd, 4th and 6th week treatment.RESULTS: The response rates in duloxetine and amitriptyline group were 86.67%(26/30)and 85.19%(23/27)respectively at the sixth weekend, the remission rates were 46.67%(14/30)and 44.44%(12/27),which showed no statistical difference between the two groups ( P>0.05). Incidences of adverse reactions in amitriptyline group was significantly higher than that in duloxetine group(77.78％ vs 36.67％, P<0.05). At the sixth weekend, all the factor scores of SF-36 in duloxetine group were significantly higher than those in control group (P<0.05). The improvement of the most factor scores of SF-36 after 6-week treatment was positively correlated with the decrease rates of total score of HAMD and HAMA, and negatively correlated with the total score of TESS (P<0.05).CONCLUSION: Duloxetine is better than amitriptyline in the improvement of quality of life in depression patients. The quality of life in depression patients is closely correlated to their depression, anxiety symptom and treatment emergent side effects.

Key words: Depression, Quality of life, Duloxetine, Amitriptyline , , , ,

中图分类号:

R749

引用本文

王继辉, 吴小立, 魏钦令, 韩自力. 度洛西汀和阿米替林对抑郁症患者生命质量的影响[J]. 中国临床药理学与治疗学, 2011, 16(1): 67-71.

WANG Ji-hui, WU Xiao-li, WEI Qin-ling, HAN Zi-li. A comparative study of efficacy on the quality of life between duloxetine and amitriptyline in treating patients with depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 67-71.

使用本文

0
/ / 推荐

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://manu41.magtech.com.cn/Jweb_clyl/CN/

https://manu41.magtech.com.cn/Jweb_clyl/CN/Y2011/V16/I1/67

参考文献

[1] Strine TW, Kroenke K, Dhingra S, et al. The associations between depression, health-related quality of life, social support, life satisfaction, and disability in community-dwelling US adults [J]. J Nerv Ment Dis,2009,197(1):61-64.
[2] Kennedy SH, Eisfeld BS, Cooke RG. Quality of life: an important dimension in assessing the treatment of depression [J]? J Psychiatry Neurosci,2001,26 Suppl:S23-28.
[3] 国效峰,赵靖平,陈晋东.度洛西汀,一种新型抗抑郁药 [J].中国新药与临床杂志,2006,25(7):552-555.
[4] 中华医学会精神科分会.中国精神障碍分类与诊断标准 [M].3版.济南:山东科学技术出版社, 2001:107-108.
[5] 纪术茂,房明,吴斌, 等.汉弥顿焦虑量表 [M]//张作记,主编.行为医学量表手册.北京:中华医学电子音像出版社,2005:214-215.
[6] 纪术茂,高成阁,吴斌, 等.汉弥顿抑郁量表[M]//张作记,主编.行为医学量表手册.北京:中华医学电子音像出版社,2005:225-227.
[7] 方积乾,郝元涛.健康状况调查问卷 [M]//张作记,主编.行为医学量表手册.北京:中华医学电子音像出版社,2005:54-59.
[8] 沈鑫华,钱敏才,林敏,等.度洛西汀和舍曲林治疗抑郁症的对照研究 [J].中国临床药理学与治疗学,2009,14(2):207-209.
[9] 马元业,任俊赏,王润泽.度洛西汀与阿米替林治疗首发抑郁症的比较分析[J].四川精神卫生,2009,22(4):233-225.
[10]Mathur A, Sharma DK, Choudhary A, et al. Efficacy and safety of citalopram versus amitriptyline in the treatment of major depression [J]. Indian J Psychiatry,2005 ,47(2):89-93.
[11]骆艳丽,吴文源,李春波,等.持续性躯体形式疼痛障碍生命质量的相关因素研究[J].上海精神医学,2007,19(1):19-22.
[12]Dunner DL, Kwong WJ, Houser TL, et al. Improved health-related quality of life and reduced productivity loss after treatment with bupropion sustained release: a study in patients with major depression [J]. Prim Care Companion J Clin Psychiatry,2001,3(1):10-16.
[13]Yen CF, Cheng CP, Huang CF, et al. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission [J]. Bipolar Disord, 2008,10(5):617-624.

相关文章 15

[1] 何滕, 许向阳, 徐祥清, 刘存明, 杨春. 氯胺酮治疗抑郁症的过去、现在及未来[J]. 中国临床药理学与治疗学, 2022, 27(10): 1125-1132.

[2] 王叶情, 王宇红, 刘检, 赵洪庆, 邹蔓姝. 胆囊收缩素与抑郁症的相关性研究进展[J]. 中国临床药理学与治疗学, 2021, 26(6): 672-679.

[3] 陈颖, 袁勇贵. 中药单体、药对、复方、中成药治疗抑郁症研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 586-593.

[4] 金晶, 程虹. 线粒体能量代谢参与抑郁症发病的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1193-1199.

[5] 杨世涛, 祝一虹, 唐文新. 阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 937-942.

[6] 冯睿，张佳莉，赫明超，李钺，张岩. 中药及其活性成分防治抑郁症的药理靶点与临床应用[J]. 中国临床药理学与治疗学, 2020, 25(4): 467-474.

[7] 周严灿. 阿戈美拉汀治疗抑郁障碍的疗效及对脑源性神经营养因子的影响[J]. 中国临床药理学与治疗学, 2019, 24(6): 699-703.

[8] 王恩特，张晓丹，周双，赵侠，周颖, 崔一民. 基因多态性对阿米替林代谢动力学、药效学和不良反应的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 235-240.

[9] 吴梦瑶赵洪庆王宇红. 抑郁症相关离子通道研究进展[J]. 中国临床药理学与治疗学, 2018, 23(8): 949-954.

[10] 莫亚莉，夏泳，刘义，陶云海，金曼. 石杉碱甲联合艾司西酞普兰对抑郁症临床疗效及认知功能的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1040-1044.

[11] 徐道祥，史惠敏，林小东. 盐酸帕罗西汀联合丹栀逍遥丸治疗抑郁症伴焦虑的临床对照研究[J]. 中国临床药理学与治疗学, 2017, 22(3): 321-325.

[12] 钟智勇，陶炯，王相兰，韩洪瀛，李凌江. 抗抑郁药物联合短期无抽搐电休克治疗对抑郁症疗效及认知功能的影响[J]. 中国临床药理学与治疗学, 2017, 22(2): 179-183.

[13] 徐象威，陈银巧，朱佩祯. 阿米替林联合阿片类药物治疗中重度癌痛伴抑郁患者疗效分析[J]. 中国临床药理学与治疗学, 2017, 22(10): 1145-1151.

[14] 陈嘉仁，崔雨迪，田灏，王昊. 沃替西汀治疗重度抑郁症的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(1): 52-59.

[15] 齐卫卫，钟正灵，郭亚鹏，李须逸，童九翠. BDNF信号通路在天然抗抑郁药中的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(9): 1068-1073.

编辑推荐

Metrics

阅读次数

全文

摘要

本文评价

摘要

参考文献

相关文章

编辑推荐

Metrics

本文评价

回顶部